Annual Report FY26 - PAT up 74%, revenue up 10%, dividend raised to 600%

Pat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

IPCALAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.1%Reaction day

₹1824.90

prior close

₹1839.00

announcement price

In-mkt

timing

Nifty Midcap 150market-0.5%+0.6% vs market

Pharmaceuticals peers, median of 166sector-0.3%+0.4% vs sector

On the reaction day the stock moved 0.6 pts more than Nifty Midcap 150 and 0.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-0.6

15m

-0.7

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.1-0.5+0.6-0.3+0.4

Next day

+2.2-0.1+2.3-0.3+2.5

+3.2-0.5+3.6-0.3+3.5

+6.3-0.9+7.1-1.3+7.6

+0.3-0.4+0.6-0.8+1.1

-1.6+0.0-1.6-0.7-0.9

-2.9-2.0-1.0-2.9-0.0

15d

-7.0+0.8-7.8-2.1-4.9

-5.0+1.1-6.1-0.8-4.2

+6.2-3.5+9.7-1.1+7.4

+4.7-5.8+10.6-2.7+7.5

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Ipca Labs posted FY26 standalone total income of Rs 7,431 crore, up 10% from Rs 6,749 crore. Net profit jumped 74% to Rs 1,132.5 crore from Rs 650.8 crore. EBITDA rose 22.5% to Rs 1,942 crore with margins improving to 26.1% from 23.5%. EPS climbed to Rs 44.64 from Rs 25.65. Dividend raised to 600% from 400%. 76th AGM scheduled for 13 August 2026.

Likely market impact

Strong earnings with 74% PAT growth, margin expansion, and higher dividend signal robust momentum for shareholders.